Zobrazeno 1 - 10
of 37
pro vyhledávání: '"J. S. Rasey"'
Autor:
J. S. Rasey, D. C. Wilson, L. K. Chin, Janet F. Eary, Lanell M. Peterson, Kenneth A. Krohn, P. D. Hofstrand, John R. Grierson, Joseph Rajendran, James D. Bruckner, Ernest U. Conrad
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 30:695-704
Hypoxia imparts resistance to radiotherapy and chemotherapy and also promotes a variety of changes in tumor biology through inducible promoters. The purpose of this study was to evaluate the use of positron emission tomography (PET) imaging with fluo
Publikováno v:
Scopus-Elsevier
Six rodent cell lines (36B10 rat glioma cells, 9L rat gliosarcoma cells, V79 Chinese hamster lung fibroblasts, EMT6/UW and EMT6/Ro mouse mammary sarcoma cells, and RIF-1 mouse fibrosarcoma cells) were tested for growth in cylindrical threads of Matri
Publikováno v:
Medical Physics. 22:1127-1139
[F-18]fluoromisonidazole (FMISO), a positron-emitting nitroimidazole, binds preferentially to hypoxic cells. It has been used to image hypoxia in human tumors with positron emission tomography (PET). In order to quantify tumor oxygenation status from
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(6)
Fluorinated derivatives of etanidazole are being explored as probes for tumor hypoxia. Our research group has synthesized [18F]fluoroetanidazole (FETA) and now reports the oxygen dependency of binding to cells in vitro, the biodistribution of the tra
Autor:
M M, Graham, L M, Peterson, J M, Link, M L, Evans, J S, Rasey, W J, Koh, J H, Caldwell, K A, Krohn
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 38(10)
Fluoromisonidazole (FMISO), labeled with the positron emitter 18F, is a useful hypoxia imaging agent for PET studies, with potential applications in patients with tumors, cardiovascular disease and stroke.Radiation doses were calculated in patients u
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 36(9)
Fluorine-18-fluoromisonidazole (FMISO) is trapped in hypoxic but viable canine myocardium. Because of the potential for its use as a marker of myocardial viability, we compared FMISO activity to [18F]fluorodeoxyglucose (FDG) activity in the same myoc
Publikováno v:
Radiation research. 142(2)
To demonstrate the effect of gamma radiation on proliferating smooth muscle cells in vivo, a standardized bilateral carotid balloon catheter arterial injury was produced in 45 rats and doses from 0-20 Gy were delivered to the right carotid artery at
Autor:
J J, Casciari, J S, Rasey
Publikováno v:
Radiation research. 141(1)
Fluoromisonidazole [1-(2-nitroimidazolyl)-2-hydroxy-3-fluoropropane, FMISO] shows promise as a hypoxia imaging agent: it binds preferentially to anoxic cells in monolayers in vitro and accumulates in radiobiologically hypoxic tumors in vivo. The mult
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 34(6)
Misonidazole and related compounds are metabolically trapped in viable cells as a function of reduced cellular pO2. [18F]fluoromisonidazole has been used to detect hypoxia in the heart and in tumors noninvasively with positron emission tomography. Th
Autor:
G V, Martin, J H, Caldwell, M M, Graham, J R, Grierson, K, Kroll, M J, Cowan, T K, Lewellen, J S, Rasey, J J, Casciari, K A, Krohn
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 33(12)
Fluoromisonidazole (FMISO) is metabolically trapped in viable cells as a function of reduced cellular pO2. Therefore [18F]-FMISO is potentially useful for evaluating patients with hypoxic but viable myocardium. The goal of this study was to investiga